title: From the first to the third generation adenoviral vector: what parameters are governing the production yield?
abstract: Human adenoviral viral vector serotype 5 (AdV) is presently the primary viral vector used in gene therapy trials. Advancements in AdV process development directly contribute to the clinical application and commercialization of the AdV gene delivery technology. Notably, the development of AdV production in suspension culture has driven the increase in AdV volumetric and specific productivity, therefore providing large quantities of AdV required for clinical studies. This review focuses on detailing the viral, cell and cell culture parameters governing the productivity of the three generations of AdV vectors.
authors.affiliation: Animal Cell Technology Group, Biotechnology Research Institute, National Research Council Canada, 6100 Royalmount Avenue, Montréal, Québec H4P2R2, Canada.
authors.forename: E
authors.initials: E
authors.lastname: Dormond
authors.forename: M
authors.initials: M
authors.lastname: Perrier
authors.forename: A
authors.initials: A
authors.lastname: Kamen
mesh_terms: D000256:Adenoviridae / Q000235:genetics* / Q000502:physiology*; D002452:Cell Count; D018929:Cell Culture Techniques; D002478:Cells, Cultured; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006801:Humans; D014771:Virion / Q000378:metabolism*; D014776:Virus Cultivation / Q000379:methods*